109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
系统性炎症评分对接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者的预后价值：一项前瞻性队列研究
Authors Wang X , Wang L , Qi Y , Liu Y, Zhang Y, Song G , Sun Q , Wei C , Liu J, Shi F , Sun L
Received 5 June 2025
Accepted for publication 3 November 2025
Published 8 November 2025 Volume 2025:18 Pages 15627—15643
DOI https://doi.org/10.2147/JIR.S542513
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Rongxue Wu
Xinchen Wang,1,* Linlin Wang,1,* Yuewen Qi,2,3 Yan Liu,1 Ying Zhang,1,2,4 Ge Song,1 Qiyu Sun,3 Chen Wei,1 Jingyi Liu,1,2,4 Fei Shi,1,2,4 Lixian Sun1,2,4
1Department of Cardiology, The Affiliated Hospital of Chengde Medical University, Chengde, People’s Republic of China; 2Hebei Key Laboratory of Panvascular Diseases, Chengde, People’s Republic of China; 3Central Laboratory, The Affiliated Hospital of Chengde Medical University, Chengde, People’s Republic of China; 4The Cardiovascular Research Institute of Chengde, Chengde, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lixian Sun, Department of Cardiology, The Affiliated Hospital of Chengde Medical University, No. 36, Nanyingzi Street, Shuangqiao District, Chengde, Hebei Province, 067000, People’s Republic of China, Tel +86 0314 227 9016, Fax +86 0314 227 4895, Email lixiansun01@126.com
Background: Acute coronary syndrome (ACS) is closely associated with inflammation status. The systemic inflammation score (SIS), which is calculated using the serum albumin level and lymphocyte-to-monocyte ratio (LMR), has emerged as a valuable biomarker for predicting the clinical outcomes of several diseases. Nonetheless, the value of SIS in predicting the long-term prognostic risk in patients with ACS undergoing percutaneous coronary intervention (PCI) remains unknown. We aimed to explore the associations of SIS with major adverse cardiovascular events (MACEs), all-cause mortality, and cardiovascular death.
Methods: This prospective cohort study consecutively enrolled 1582 patients with ACS who underwent PCI at the Department of Cardiology in the Affiliated Hospital of Chengde Medical University (Chengde, China) between January 2016 and December 2018. The primary endpoint was MACEs, including all-cause mortality, rehospitalization for heart failure, revascularization, recurrence of acute myocardial infarction, and restenosis/intrastent thrombosis.
Results: The Kaplan–Meier survival analysis revealed that a high SIS was correlated with MACEs and all-cause mortality and that increasing SIS was independently associated with the risks of MACEs and all-cause mortality by Cox regression. Landmark analysis provided evidence for the time window of predictive ability, which could guide clinical applications. A clear correlation between the increasing tendency of hazard ratio in patients with ACS undergoing PCI and the risks of MACEs or all-cause mortality was noted (p for trend < 0.05). The sensitivity analysis with a competing risk model showed that high SIS level was correlated with the risks of cardiac death and rehospitalization. The mediation analysis revealed that the hemoglobin level exerted a mediating effect on the relationship between SIS and MACEs.
Conclusion: The SIS exhibited a strong correlation with the risks of MACEs and all-cause mortality. Notably, the SIS was particularly effective in predicting the risk of cardiac death and likelihood of rehospitalization.
Keywords: acute coronary syndrome, prognosis, systemic inflammation score, percutaneous coronary intervention
1Department of Cardiology, The Affiliated Hospital of Chengde Medical University, Chengde, People’s Republic of China; 2Hebei Key Laboratory of Panvascular Diseases, Chengde, People’s Republic of China; 3Central Laboratory, The Affiliated Hospital of Chengde Medical University, Chengde, People’s Republic of China; 4The Cardiovascular Research Institute of Chengde, Chengde, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lixian Sun, Department of Cardiology, The Affiliated Hospital of Chengde Medical University, No. 36, Nanyingzi Street, Shuangqiao District, Chengde, Hebei Province, 067000, People’s Republic of China, Tel +86 0314 227 9016, Fax +86 0314 227 4895, Email lixiansun01@126.com
Background: Acute coronary syndrome (ACS) is closely associated with inflammation status. The systemic inflammation score (SIS), which is calculated using the serum albumin level and lymphocyte-to-monocyte ratio (LMR), has emerged as a valuable biomarker for predicting the clinical outcomes of several diseases. Nonetheless, the value of SIS in predicting the long-term prognostic risk in patients with ACS undergoing percutaneous coronary intervention (PCI) remains unknown. We aimed to explore the associations of SIS with major adverse cardiovascular events (MACEs), all-cause mortality, and cardiovascular death.
Methods: This prospective cohort study consecutively enrolled 1582 patients with ACS who underwent PCI at the Department of Cardiology in the Affiliated Hospital of Chengde Medical University (Chengde, China) between January 2016 and December 2018. The primary endpoint was MACEs, including all-cause mortality, rehospitalization for heart failure, revascularization, recurrence of acute myocardial infarction, and restenosis/intrastent thrombosis.
Results: The Kaplan–Meier survival analysis revealed that a high SIS was correlated with MACEs and all-cause mortality and that increasing SIS was independently associated with the risks of MACEs and all-cause mortality by Cox regression. Landmark analysis provided evidence for the time window of predictive ability, which could guide clinical applications. A clear correlation between the increasing tendency of hazard ratio in patients with ACS undergoing PCI and the risks of MACEs or all-cause mortality was noted (p for trend < 0.05). The sensitivity analysis with a competing risk model showed that high SIS level was correlated with the risks of cardiac death and rehospitalization. The mediation analysis revealed that the hemoglobin level exerted a mediating effect on the relationship between SIS and MACEs.
Conclusion: The SIS exhibited a strong correlation with the risks of MACEs and all-cause mortality. Notably, the SIS was particularly effective in predicting the risk of cardiac death and likelihood of rehospitalization.
Keywords: acute coronary syndrome, prognosis, systemic inflammation score, percutaneous coronary intervention